Athanor Capital, LP Neurocrine Biosciences Inc Transaction History

Athanor Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $1.05 Million - $1.44 Million	-12,022 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.24 Million - $1.55 Million	-14,296 Reduced 54.32%	12,022 $1.15 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $1.14 Million - $1.6 Million	11,865 Added 82.09%	26,318 $2.53 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $1.23 Million - $1.88 Million	14,453 New	14,453 $1.76 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $976,430 - $1.48 Million	-13,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $164,920 - $225,283	1,900 Added 17.12%	13,000 $1.4 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $930,401 - $1.13 Million	11,100 New	11,100 $1 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.